• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

major depressive disorder

Brown mouse nibbling a cookie
Research

GLP-1s may combat depression through a mood-boosting gut microbe

GLP-1s upped levels of the bacteria Lactobacillus delbrueckii in the guts of mice, which in turn churn out compounds with antidepressant effects.
Darren Incorvaia Jun 10, 2026 11:00am
A collection of the fungus among us

Compass, Usona and Transcend score priority vouchers amid psychedelic push

Apr 24, 2026 3:51pm
human brain abstract art

Biohaven flunks depression trial, adding to CNS release concerns

Jan 2, 2026 4:48am
colorful brain art model

Neurocrine-Takeda psychiatry pact suffers another phase 2 fail

Nov 11, 2025 6:25am
Brain and money connected by a thread on a white background

AbbVie inks $1.2B deal to buy Gilgamesh's psychedelic program

Aug 25, 2025 9:42am
pivot change turnaround direction walk away

HMNC recalibrates precision depression push after phase 2b miss

Aug 5, 2025 10:38am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings